EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities

Yating Dian, Yu Meng, Yuming Sun, Guangtong Deng, Furong Zeng

Journal of Infection · 2023

DOI: 10.1016/j.jinf.2023.05.012 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Infection, 2023. Verfasst von Yating Dian und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; National Engineering Research Center of Persona…. Hauptthemen laut MEDLINE: COVID-19, Antiviral Agents, COVID-19 Drug Treatment. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province, Xiangya Hospital, Central South University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antiviral AgentsCOVID-19 Drug TreatmentHumansAzidesEast Asian PeopleComorbidityDeoxycytidineDrug CombinationsLactamsLeucineNitrilesProlineRitonavir

Substanzen

AzidesAntiviral AgentsazvudineDeoxycytidinenirmatrelvir and ritonavir drug combinationDrug CombinationsLactamsLeucineNitrilesProline

Autor:innen und Institutionen

  • Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, China; Furong Laboratory,…
  • Department of Plastic and Cosmetic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
  • Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China. Electronic address: zengflorachn@hotmail.com.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province
  • Xiangya Hospital, Central South University

Zitieren

APA

Dian, Y., Meng, Y., Sun, Y., Deng, G., & Zeng, F. (2023). Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities. Journal of Infection. https://doi.org/10.1016/j.jinf.2023.05.012

Vancouver

Dian Y, Meng Y, Sun Y, Deng G, Zeng F. Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities. Journal of Infection. 2023. doi:10.1016/j.jinf.2023.05.012

BibTeX
@article{Dian2023,
  author = {Dian, Yating and Meng, Yu and Sun, Yuming and Deng, Guangtong and Zeng, Furong},
  title = {Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities},
  journal = {Journal of Infection},
  year = {2023},
  doi = {10.1016/j.jinf.2023.05.012}
}
Kostenlos starten →